• Home
  • News
  • Stephenson Harwood advises Acacia Pharma on $30 million credit facility

17 Jul 2018

Stephenson Harwood advises Acacia Pharma on $30 million credit facility


Law firm Stephenson Harwood LLP has advised Acacia Pharma Group on a $30 million credit facility from Hercules Technology Growth Capital.

Acacia Pharma, a hospital pharmaceutical company focused on the development of new nausea and vomiting treatments for surgical and cancer patients, will use the $30 million credit facility to support the planned US launch of drug BARHEMSYS TM, also known as amisulpride. The loan from Hercules Technology Growth Capital, a California-based specialty finance company, will enable Acacia Pharma to continue the commercialisation of its product and establish strategic relationships in the US pharmaceutical market.

The Stephenson Harwood team was led by London-based corporate partner Anthony Clare along with finance partner James Linforth, and included associate Gabriella McCoy and tax associate Hilary Barclay.

This is the second matter on which Stephenson Harwood has recently advised Acacia Pharma, having supported the company on its €190 million Euronext Brussels IPO earlier this year; the listing was the largest on Euronext since 2015 and was the first IPO of a British-based biotech company in 2018.



Anthony Clare

Anthony Clare

T:  +44 20 7809 2326 M:  +44 7711 345 399 Email Anthony | Vcard Office:  London

James Linforth

James Linforth

T:  +44 20 7809 2060 M:  Email James | Vcard Office:  London


Rose Russell
Communications & PR Executive

T: +44 20 7809 2961 
Email Rose

  • Related Services
  • Related Locations